Review
Hematology
Maria Domenica Cappellini, Ali T. Taher, Amit Verma, Farrukh Shah, Olivier Hermine
Summary: Hematologic disorders like myelodysplastic syndromes and beta-thalassemia are characterized by ineffective erythropoiesis and anemia, usually managed through regular blood transfusions. However, treatments targeting the underlying mechanisms of ineffective erythropoiesis are limited, leading to a burden on patients, caregivers, and healthcare systems. This article provides an overview of the role of ineffective erythropoiesis in these disorders, discusses unmet needs in targeting it, and describes current management strategies and emerging treatments.
Article
Hematology
Irina Amitai, Michelle Geddes, Nancy Zhu, Mary-Margaret Keating, Mitchell Sabloff, Grace Christou, Brian Leber, Dina Khalaf, Heather A. Leitch, Eve St-Hilaire, Nicholas Finn, April Shamy, Karen Yee, John Storring, Thomas Nevill, Robert Delage, Mohamed Elemary, Versha Banerji, Lisa Chodirker, Lee Mozessohn, Anne Parmentier, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Rena Buckstein
Summary: Incorporating patient-reported fatigue with traditional risk classification enhances survival prediction in higher-risk MDS patients, leading to distinct subgroups with different survival outcomes. This highlights the importance of considering patient-reported outcomes in refining overall survival predictions for higher-risk MDS.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Andrew M. Brunner, Heather A. Leitch, Arjan A. van de Loosdrecht, Nicolas Bonadies
Summary: This review focuses on the diagnosis, prognosis, and treatment options for patients with lower-risk myelodysplastic syndromes (LR-MDS). It discusses the prediction of disease progression and monitoring of treatment response. The review also explores how next-generation sequencing and novel therapies may impact the treatment landscape for LR-MDS, as well as the importance of incorporating structured assessments into routine clinical practice.
BLOOD CANCER JOURNAL
(2022)
Article
Hematology
Vladimir Riabov, Maximilian Mossner, Alexandra Stoehr, Johann-Christoph Jann, Alexander Streuer, Nanni Schmitt, Antje Knaflic, Verena Nowak, Nadine Weimer, Julia Oblaender, Iris Palme, Christiane Schumann, Claudia D. Baldus, Torsten J. Schulze, Patrick Wuchter, Henning Roehl, Ahmed Jawhar, Christel Weiss, Tobias Boch, Georgia Metzgeroth, Martin Neumann, Wolf-Karsten Hofmann, Florian Nolte, Daniel Nowak
Summary: The expression of ERFE and GDF15 in MDS patients was found to be highly aberrant, with ERFE expression unexpectedly relevant for MDS prognosis. ERFE overexpression predicted superior overall survival in certain MDS subgroups, suggesting a possible involvement of ERFE in the molecular pathogenesis of MDS.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Medicine, General & Internal
Kathrin Nachtkamp, Guido Kobbe, Norbert Gattermann, Ulrich Germing
Summary: Myelodysplastic syndromes (MDS) are malignant diseases arising from hematopoietic stem cells, with an incidence of 4 cases per 100,000 persons per year. They are usually diagnosed when evaluating cytopenia, and the median survival time is three years. This review summarizes the latest research on the diagnosis and treatment of MDS.
DEUTSCHES ARZTEBLATT INTERNATIONAL
(2023)
Article
Medicine, General & Internal
Felicitas Schulz, Ulrich Hauch, Sandra Ketzler-Henkel, Eyck von der Heyde, Michael Koenigsmann, Michael Lauseker, Nora Schulte, Ulrich Germing
Summary: Myelodysplastic syndromes and myeloproliferative neoplasms are hematologic diseases associated with bone marrow failure, and transfusion of red blood cells is necessary but leads to iron overload. Therefore, iron chelation therapy plays a crucial role in anemic patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Esther Natalie Oliva, Krystal Huey, Sohan Deshpande, Monica Turner, Madhura Chitnis, Emma Schiller, Derek Tang, Aylin Yucel, Christina Hughes, Farrukh Shah
Summary: High serum ferritin (SF) levels are associated with worse prognosis in MDS patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Mathias Schneeweiss-Gleixner, Georg Greiner, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, Karoline Gleixner, Friedrich Wimazal, Corinna Steinhauser, Michael Kundi, Renate Thalhammer, Ilse Schwarzinger, Gregor Hoermann, Harald Esterbauer, Manuela Fodinger, Peter Valent, Wolfgang R. Sperr
Summary: Although iron overload is a clinical challenge, little is known about the clinical impact of HFE-variants in myelodysplastic syndromes. The study found that HFE-variants H63D and C282Y are frequently detected in Austrian MDS patients, who have higher ferritin levels at diagnosis, accumulate iron slightly faster, and have a better progression-free survival than non-mutated patients.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Annika Kasprzak, Kathrin Nachtkamp, Norbert Gattermann, Ulrich Germing
Summary: This article discusses the prognostic scoring systems for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It highlights the limitations of current scoring systems and emphasizes the importance of patient and disease-related parameters in assessing prognosis. The article also identifies areas for further investigation.
Article
Biochemistry & Molecular Biology
Xiaoqing Xie, Daria Frank, Pradeep Kumar Patnana, Judith Schuette, Yahya Al-Matary, Longlong Liu, Lanying Wei, Martin Dugas, Julian Varghese, Subbaiah Chary Nimmagadda, Cyrus Khandanpour
Summary: The study identified a therapeutic role for curcumin treatment in delaying the expansion of GFI1-36N or -KD, NUP98-HODXD13 leukemic cells and prolonging AML-free survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Esther Natalie Oliva, Marta Riva, Pasquale Niscola, Valeria Santini, Massimo Breccia, Valentina Giai, Antonella Poloni, Andrea Patriarca, Elena Crisa, Isabella Capodanno, Prassede Salutari, Gianluigi Reda, Nicola Cascavilla, Dario Ferrero, Attilio Guarini, Giovanni Tripepi, Giuseppe Ianni, Emilio Russo, Andrea Castelli, Bruno Fattizzo, Germana Beltrami, Monica Bocchia, Alfredo Molteni, Pierre Fenaux, Ulrich Germing, Alessandra Ricco, Giuseppe A. Palumbo, Stefana Impera, Nicola Di Renzo, Flavia Rivellini, Francesco Buccisano, Aspasia Stamatoullas-Bastard, Anna Marina Liberati, Anna Candoni, Ilaria Maria Delfino, Maria Teresa Arcadi, Patrizia Cufari, Lorenzo Rizzo, Irene Bova, Maria Grazia D'Errigo, Gina Zini, Roberto Latagliata
Summary: This study demonstrates the efficacy and safety of eltrombopag in treating low-risk MDS patients with severe thrombocytopenia. Eltrombopag significantly increases the duration of platelet response and reduces the incidence of clinically significant bleeding.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Jan Philipp Bewersdorf, Amer M. Zeidan
Summary: MDS and CMML are two distinct blood cancers with variable symptoms and risks. Management decisions should be individualized and based on validated risk stratification tools. Supportive care is the mainstay for lower-risk patients, while bone marrow transplant is the only curative option for higher-risk patients.
Review
Oncology
Cecilia H. Kim, Heather A. Leitch
Summary: Iron overload-induced reactive oxygen species affect cellular activities, leading to dysfunction in hematopoietic stem cells and other cells, exacerbating the pathophysiology of myelodysplastic syndromes.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Yao Zhang, Chao Xiao, Jing Li, Lu-xi Song, You-shan Zhao, Shuang Han, Zhao-wei Li, Cha Guo, Jun-gong Zhao, Chun-kang Chang
Summary: DECT and MRI were complementary in liver iron detection, with DECT being more reliable than MRI in MDS patients with high iron content. MRI was more reliable than DECT in patients with low iron content. The appropriate detection method can be selected according to ASF for more accurate evaluation of iron content.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Chantana Polprasert, Pimjai Niparuck, Thanawat Rattanathammethee, Suporn Chuncharunee, Sirorat Kobbuaklee, Kritanan Songserm, Amornchai Suksusut, Sasinipa Trithiphen, Theerin Lanamtieng, Sunisa Kongkiatkamon, Chantiya Chanswangphuwana, Panisinee Lawasut, Udomsak Bunworasate, Ponlapat Rojnuckarin
Summary: Mutation detection is important for proper risk stratification of patients presenting with idiopathic cytopenia. ASXL1 and DNMT3A mutations in low-risk MDS patients are associated with a higher risk of disease progression.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
